Clinical trial · Observational
Antitumor T Cell Responses in Patients With Bladder Cancer
Study of Antitumor T Cell Immune Responses in Patients With Bladder Cancer
NCT06334406CI-TRIAL-00075509immunoBLADunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main objective of this study is to evaluate the induction of Th1 anti-TERT responses by treatments in patients with bladder tumor.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Biological samples | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Cohort A
- description
- Patients treated with intravesical instillations for non-invasive bladder cancer
- interventionNames
- Other: Biological samples
- label
- Cohort B
- description
- Patients treated with radiotherapy (+/- concurrent chemotherapy) for invasive bladder cancer
- interventionNames
- Other: Biological samples
- label
- Cohort C
- description
- Patients treated with neo-adjuvant chemotherapy for invasive bladder cancer
- interventionNames
- Other: Biological samples
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients undergoing transurethral resection of the bladder (TURBT) for a tumor detected by cystoscopy with a histological diagnosis of a non-infiltrating or muscle-infiltrating tumor * For muscle-invasive tumors: localized tumors (T2-T3N0M0) or locally advanced (T4N0M0) * Written informed consent Exclusion Criteria: * History of TURBT for a bladder tumor whatever the stage * Stages N1-3 or M1 on initial assessment * Patients under immunotherapy, chemotherapy or other immunosuppressive drugs (prednisone or prednisolone ≤ 10 mg/day is allowed) * History of cancer in the last 3 years other than basal cell carcinoma or non-invasive cervical cancer * HIV, hepatitis C or B infection * Patients with any medical or psychiatric condition or disease, * Patients under guardianship, curatorship or under the protection of justice.
References
Publications (0)
Data not yet available
No reference posted for this study.